我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

rHuEPO对维持性血液透析患者心功能的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2008年第3期
页码:
340-341，347
栏目:
临床研究
出版日期:
2008-05-20

文章信息/Info

Title:
Effects of rHuEPO on cardiac structure and function in maintenance hemodialysis patients
作者:
方玲; 赵治华; 武明; 闫瑞玲; 郑宏; 张国芳
兰州军区兰州总医院普通内科，甘肃 兰州 730050
Author(s):
FANG Ling;  ZHAO Zhihua;  WU Ming;  YAN Ruiling;  ZHENG Hong;  ZHANG Guofang
Department of General Medicine, PLA Lanzhou General Hospital, Lanzhou Military Area Command, Lanzhou 730050, Gansu, China
关键词:
促红细胞生成素; 肾性贫血; 血液透析; 心脏功能
Keywords:
erythropoietin;  renal anemia;  hemodialysis;  cardiographic parameters
分类号:
R692.6
DOI:
-
文献标识码:
A
摘要:
目的 观察组重组人红细胞生成素(rHuEPO)对维持性血液透析患者心功能的影响。方法 将36例患者按2∶1比例分入rHuEPO治疗组和对照组。治疗前及治疗后观察血色素(Hb)以及心脏彩超测定左室舒张末期内径（LVEDD）、左室收缩末期内径（LVESD），室间隔厚度(IVST)、左心室后壁厚度(LVPWT)、左房内径(LAD)。左室射血分数(LVEF)，左心室心肌质量(LVM)，并计算左室心肌质量指数(LVMI)，在二尖瓣区测量舒张早期和舒张晚期最大血流速度并计算两者的比值(E/A)等指标，并进行比较。结果 应用rHuEPO治疗6个月后，治疗组Hb、LVEDD、LAD、LVEF、LVM以及E/A均有显著性改善(均P<005)；而对照组上述指标无明显变化。结论 应用rHuEPO治疗维持性血液透析患者，不仅能改善肾性贫血，而且能明显改善心脏功能。
Abstract:
AIM To investigate the changes of the cardiac function and structure in maintenance hemodialysis (MHD) patients after treatment with rHuEPO. METHODS Thirtysix patients were randomly divided into two groups by the ratio 2∶1, with 24 patients treated with rHuEPO in therapy group and 12 patients in control group. The echocardiographic parameters （LVEDD, LVESD, IVST, LVPWT, LAD, LVEF, LVM, LVMI and E/A） and Hb were compared before and after treatment with rHuEPO. RESULTS After six months, the patients in therapy group were improved in LVEDD, LAD, LVEF, LVM, E/A and Hb, while the patients in control group kept a steady hemoglobin level and echocardiographic parameters. CONCLUSION Most of the hemodialysis patients have cardiac diastolic dysfunction and left ventricular hypertrophy. After treatment with rHuEPO for 6 moths, there are changes not only in the hemoglobin level but also in the cardiac function, structure.

参考文献/References

［1］ Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1,3, and 4 study［J］. J Am Soc Nephrol, 2005, 16(6):1788-1793.

［2］ Goicoechea M, de Vinuesa SG, GómezCampder F, et al. Predictive cardiovascular risk factors in patients with chronic kidney disease (CKD)［J］. Kidney Int Suppl, 2005, (93):S35-S38.

［3］ 王新房. 超声心动图［M］. 北京: 人民卫生出版社, 1999:301-314.

［4］ Hassan K, Roguin N, Kaganov Y, et al. Effect of erythropoietin therapy on red cells filterability and left ventricular mass in predialysis patients［J］. Ren Fail, 2005, 27(2):177-182.

［5］ Foppa M, Duncan BB, Rohde LE. Echocardiographybased left ventricular mass estimation. How should we define hypertrophy?［J］ Cardiovasc Ultrasound, 2005, 3:17.

［6］ van der Meer P, Voors AA, Lipsic E, et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure［J］. J Am Coll Cardiol, 2004, 44(1):63-67.

［7］ Zaslavsky LM, Pinotti AF, Gross JL. Diastolic dysfunction and mortality in diabetic patients on hemodialysis: a 4.25year controlled prospective study［J］. J Diabetes Complications, 2005, 19(4):194-200.

［8］ Pozzoni P, Del Vecchio L, Pontoriero G, et al. Longterm outcome in hemodialysis:morbidity and mortality［J］. J Nephrol, 2004, 17(Suppl 8):S87-S95.

备注/Memo

备注/Memo:
收稿日期：2007-08-20.作者简介：方玲，副主任医师，博士 Email:fangling9999@sina.com
更新日期/Last Update: